Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corporation, often referred to simply as Acerus, is a Canadian biopharmaceutical company headquartered in Ontario, Canada. Founded in 2006, Acerus focuses on developing innovative therapeutic solutions primarily in the fields of men's health and hormone replacement therapy. The company has made significant strides with its flagship product, Natesto, a unique nasal testosterone replacement therapy that offers a convenient alternative to traditional methods. Acerus is committed to addressing unmet medical needs, positioning itself as a leader in the niche market of hormone therapies. With a strong emphasis on research and development, Acerus continues to expand its portfolio and enhance its market presence, striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Acerus Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acerus Pharmaceuticals Corporation's score of 13 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Acerus Pharmaceuticals Corporation's reported carbon emissions
Acerus Pharmaceuticals Corporation, headquartered in Canada, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data may indicate a need for enhanced transparency in their environmental strategies. As the pharmaceutical industry increasingly prioritises sustainability, Acerus may benefit from establishing clear climate commitments and reduction initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Acerus Pharmaceuticals Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
